Rheumatology key messageA second haematopoietic stem cell transplantation (HSCT) with post-HSCT immunosuppression can be considered in SSc relapse after HSCT.

[Sir]{.smallcaps}, Autologous haematopoietic stem cell transplantation (HSCT) is an effective treatment in patients with progressive diffuse cutaneous systemic sclerosis (dcSSc) \[[@kez010-B1], [@kez010-B2]\]. Unfortunately, some patients experience a relapse, which can be managed with conventional immunosuppressants in most cases. In refractory cases a second HSCT may be considered; however, data on safety and efficacy are lacking. Here, we present the case of a dcSSc patient who underwent a second HSCT and discuss our management of the patient in light of current evidence.

A 35-year-old woman with a history of RP for 1 year presented with rapidly progressive skin thickening despite treatment with MMF. Physical examination showed anterior tibial tendon friction rubs and generalized skin involvement with a modified Rodnan skin score of 26. Nailfold capillaroscopy revealed an early scleroderma pattern. Immunology showed a positive ANA, anti-RNP III and anti-SSA-52 autoantibodies. The diagnosis of dcSSc was made. There was no visceral involvement.

Taking into consideration the poor prognosis of this patient (progressive skin involvement, tendon friction rubs) and non-responsiveness to MMF, she was counselled about available treatment options and the decision to perform HSCT was made. Mobilization and pre-transplant conditioning were conducted according to the Autologous Stem Cell Transplantation International Scleroderma Trial protocol \[[@kez010-B1]\]. After conditioning with i.v. CYC and rabbit antithymocyte globulin (ATG), 315 × 10^6^ CD34^+^ cells were infused (5.25 × 10^6^/kg bodyweight). There were no adverse events during the procedure apart from a self-limiting viral respiratory tract infection.

Skin thickening significantly decreased after HSCT ([Fig. 1](#kez010-F1){ref-type="fig"}). However, almost 12 months post-HSCT, the patient developed clinical signs of a relapse; the modified Rodnan skin score had increased to 22, and tibial tendon friction rubs had returned. The patient developed severe itching, which was refractory to standard supportive and pharmacological treatment. Pulmonary function tests were unchanged, but an ECG revealed new onset of a first degree atrioventricular block. MMF, MTX and rituximab were initiated but were not effective.

![Immunological reconstitution and the mRSS\
The vertical lines denote the start of the relapse and the second HSCT. The grey bars represent mobilization phases. After HSCT, the mRSS rapidly decreased, to increase again at the onset of relapse. This coincided with immunological reconstitution. After the second HSCT, the mRSS remained low, despite reconstitution of the T cell compartment. HSCT: haematopoietic stem cell transplantation; mRSS: modified Rodnan skin score.](kez010f1){#kez010-F1}

There is little evidence to guide treatment decisions in relapse of SSc after HSCT. Data from clinical trials shows that most relapses can be treated with oral MTX and MMF \[[@kez010-B1]\]. Additionally, a small study suggested that rituximab can be used to manage post-HSCT relapse in RA \[[@kez010-B3]\]. Unfortunately, neither MTX nor rituximab were effective in our patient.

Given that symptoms recurred with T cell repopulation (see [Fig. 1](#kez010-F1){ref-type="fig"}), and the brief but very favourable response on the first HSCT, a second autologous HSCT was considered. Information on both the efficacy and safety of second HSCT is scarce \[[@kez010-B4]\]. The European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases reports nine second HSCTs, but no clinical outcome data were presented \[[@kez010-B5]\]. A single case report described a second HSCT in SSc, which induced clinical remission, but long-term follow-up data on safety was not available \[[@kez010-B6]\]. Therefore, we extensively counselled the patient about the possible risks of a second HSCT, which include secondary malignancy and cardiotoxicity as a complication of high-dose CYC administration. Other important considerations were anticipated difficulties with stem cell mobilization, and possible sensitization to ATG. It was decided to start immune suppression with ciclosporin and MMF immediately post-HSCT to maintain T cell suppression after immunological reconstitution.

The second HSCT was initiated at 18 months after the first HSCT, using the same protocol as the first HSCT. The mobilization was uneventful; no changes to the mobilization regimen were needed to harvest the required number of CD34^+^ cells through leukapheresis. No adverse events occurred during the conditioning. A total of 172 × 10^6^ cells were infused (2.93 × 10^6^/kg bodyweight). During the neutropenic phase after graft infusion, the patient developed an infected digital ulcer complicated with osteomyelitis, which was successfully treated with i.v. antibiotics.

At 18 months after the second HSCT, skin thickening has almost disappeared (modified Rodnan skin score of 4) and no new visceral involvement has occurred. Despite the favourable outcome on these aspects of the disease, the patient still experiences significant disability due to severe RP.

The pathophysiology of post-HSCT relapse is unclear, but the temporal relationship of the relapse in our patient with immune reconstitution suggests a relationship with re-emergence of autoreactive clones ([Fig. 1](#kez010-F1){ref-type="fig"}). Studies regarding correlations between immunological parameters and relapse after HSCT for dcSSc are conflicting \[[@kez010-B7]\]. At baseline, our patient had a positive ANA test (1:100), anti-RNP III antibodies and anti-SSA antibodies. Anti-SSA antibodies disappeared after the first HSCT and remained absent during the relapse, although the ANA test remained weakly positive (granular staining pattern) and RNP III antibodies persist up until now.

In conclusion, our case underscores the potential benefit of a second HSCT with post-HSCT immunosuppression in SSc patients who relapse after HSCT. However, caution should be used regarding possible toxicity and long-term side-effects and a careful screening procedure remains essential, as described by us recently \[[@kez010-B8]\]. Ultimately, the decision to perform a second HSCT requires good multidisciplinary support as well as shared decision making with the patient.
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